VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

GINA COLUMBUS and BETH FAND INCOLLINGO
After 10 years without a new drug for liver cancer, two approvals and a promising pipeline are changing the landscape.
Wayne Kuznar
Treatment with the PD-1 inhibitor Keytruda (pembrolizuumab) elicited promising progression-free survival (PFS) and overall survival (OS) results in patients with advanced hepatocellular carcinoma (HCC) who received previous treatment with Nexavar (sorafenib), according to phase 2 findings.
Silas Inman
“Patients with advanced hepatocellular carcinoma often have a poor prognosis and limited treatment options following prior systemic therapy,” lead investigator Ghassan K. Abou-Alfa, M.D.
Ghassan K. Abou-Alfa, MD, shares his excitement over the use of immunotherapy for liver cancer in 2018, and highlights research initiatives that are studying its potential in combination with other therapies.
Ghassan K. Abou-Alfa, MD, advises patients on what to expect from treatment with immunotherapy, including how your doctor monitors treatment response and manages adverse effects.
Ghassan K. Abou-Alfa, MD, explains how immunotherapy works in liver cancer and discusses the patient and disease characteristics that determine who is most likely to respond.
Ghassan K. Abou-Alfa, MD, highlights novel treatment approaches, such as immunotherapy, that are used in patients whose liver cancer has spread.
Ghassan K. Abou-Alfa, MD, discusses the challenges associated with treating liver cancer and highlights the various therapies used in the management of the disease.
Beth Fand Incollingo
People treated for liver cancer at an inner-city hospital experienced better survival odds if they had private health insurance, and also if they were married, according to the results of a recent study that considered how socioeconomic factors affect health outcomes for those with the disease.
Gina Columbus
The liver cancer treatment field has remained stagnant for years, but new agents are destined to enter the field in the near future, Ghassan K. Abou-Alfa, M.D., says.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable